The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Tafasitamab is a humanized monoclonal antibody that binds to the CD19 antigen, which is expressed in tumor cells from patients with diffuse large B-cell lymphoma (DLBCL). On June 24, 2021, a positive opinion for a conditional marketing authorization was issued by the European Medicines Agency (EMA)’...
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
Wiley
2021-12-01
|
| Schriftenreihe: | HemaSphere |
| Online Zugang: | http://journals.lww.com/10.1097/HS9.0000000000000666 |